Dr. Jimmy Lin, MD, PhD, MHS has devoted his life to beating cancer.
At Johns Hopkins, he helped perform the first genome-wide sequencing of human cancers - including colorectal, breast, pancreatic, melanoma, and brain cancers.
At the Washington University in St. Louis, he was part of one of the first academic clinical next-generation sequencing efforts.
At the National Cancer Institute (NCI) at the National Institutes of Health (NIH), he built and led the intramural clinical genomics (ClinOmics) program.
At Natera (NASDAQ: NTRA), he was the Chief Scientific Officer (CSO), Oncology that led the development of a liquid biopsy cancer monitoring diagnostic.
Currently, he is the Chief Scientific Officer (CSO) at Freenome, developing blood-based test to enable the early detection of colorectal cancer.
In addition, he has leveraged the technological advances in cancer to fight rare diseases as the Founder and President of the Rare Genomics Institute.
Researcher
Dr. Lin has published over 100+ papers, book chapters, and abstracts including top academic journals such as Science, Nature, and Cell and has spoken at top universities such as Harvard, Yale, and Stanford.
Speaker
Dr. Lin has delivered over 100+ keynotes, speeches, and panels in 19 countries on 5 continents, including TED, Aspen Ideas Festival, Google, the White House and the European Commission.
Thought Leader
Dr. Lin has been featured or mentioned in over 300+ media outlets including New York Times, Washington Post, CNN, Financial Times, Forbes, BBC, WIRED and TIME.
